Contemporary Referral Pattern for Robotic Prostatectomy by Dangle, Pankaj P. & Abaza, Ronney
Contemporary Referral Pattern for
Robotic Prostatectomy
Pankaj P. Dangle, MD, Ronney Abaza, MD
ABSTRACT
Background and Objectives: In spite of the current
widespread application of robotic surgery in the treatment
of prostate cancer, it remains unclear whether current
patterns of use are based on patient benefit or driven by
marketing. We sought to investigate this possibility by
analyzing the source of our patient population for robot-
assisted laparoscopic prostatectomy (RALP).
Methods: We reviewed 200 consecutive patients who
underwent robotic prostatectomy by a single surgeon
(RA) at our institution. The source of referral for each
patient was analyzed along with individual patient char-
acteristics to identify whether only low-risk or unusually
ideal candidates were referred.
Results: Of the 200 patients, 90.5% were referred by a
urologist with only 5.5% being referred by another urol-
ogist at our institution. Only 10 patients cited media or
marketing sources as the reason for self-referral, and 10
were referred by primary care physicians or other ac-
quaintances. This referral pattern did not change between
the first and second 100 patients. Referred patients in-
cluded those up to 80 years of age, up to 51kg/m
2 in body
mass index, and up to Gleason 9 on biopsy, with 36% of
those referred by urologists having some history of previ-
ous abdominal or prostate surgery.
Conclusion: The referral pattern for RALP at our insti-
tution may reflect a growing acceptance of robotic
surgery among urologists in our region and is unlikely
driven by patient-directed marketing. Additionally, urolo-
gists may also be more confident in the role of RALP as
evidenced by their referral of even complex and higher-
risk patients.
Key Words: Prostate cancer, Robotic-assisted laparo-
scopic prostatectomy, Motivating influences.
INTRODUCTION
Prostate cancer is the second most common solid organ
malignancy in American men. It is estimated that 192 280
men will be diagnosed with and 27 360 men will die of
prostate cancer in 2009.1 Increased awareness and screen-
ing has led to early detection of low-stage and low-vol-
ume disease in young, healthy men who are candidates
for prostatectomy.2
With technological advances in treating prostate cancer,
minimally invasive treatment options have become avail-
able, including brachytherapy, external beam radiother-
apy, high-intensity focused ultrasound (HIFU), and cryo-
therapy.1,3 Nevertheless, radical prostatectomy is still
considered the gold standard for the treatment of localized
prostate cancer.4 Laparoscopic and robot-assisted laparo-
scopic prostatectomy (RALP) have been promoted as less
invasive with potentially less pain and quicker recovery.1,5
Regardless of the therapeutic approach, the primary ob-
jective in the treatment of prostate cancer is cure, with the
secondary aim of delivering the treatment with minimal
morbidity.6
Since FDA approval of the da Vinci robotic surgical system
in 2000, the number of RALP procedures performed in the
United States has continued to climb, with approximately
80 000 performed in 2008.7 As with any new technology,
purveyors of a new instrument or device develop an
associated marketing strategy to accelerate adoption.
Within 3 years of the first report of RALP in 2000, series
including hundreds of patients appeared in the literature,
reflecting individual institution’s ability to regionalize care
for prostate cancer by offering robotic surgery.8 Many
institutions have reported significant benefits of RALP
over open surgery in the form of minimal morbidity, faster
recovery, and in some cases better oncologic and func-
tional outcomes.7,8
During the initial adoption of robotic surgery, challenges,
such as the robotic learning curve, technical challenges
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SCIENTIFIC PAPERand mechanical failures, were faced. These factors added
to doubts regarding potential advantages of the robotic
approach over the traditional open surgical approach.
Since then, many of these stumbling blocks have been
negotiated as the pioneers have perfected their techniques
and passed along their refinements to a new generation of
robotic surgeons emerging from their training programs
already facile with robotics.
It remains difficult to assess whether current practice pat-
terns for treating prostate cancer are evidence-based or
driven by marketing. Many still feel and fear that market-
ing continues to fuel the adoption of robotic technology.
Additionally, some have challenged the reported results of
RALP by asserting that it has been inequitably applied to
an “ideal” patient base with minimal disease and/or favor-
able prostate and abdominal anatomy, thereby biasing
results in favor of RALP over those for whom only open
surgery was offered.
We sought to assess acceptance of robotic technology
among urologists in our community by analysis of the
source of our patient population for RALP. We also ana-
lyzed preoperative patient characteristics to determine
whether patients presenting for RALP were of an ideal
patient base unrepresentative of the typical prostate can-
cer population.
MATERIALS AND METHODS
We reviewed 200 consecutive patients who underwent
robotic-assisted laparoscopic prostatectomy at The James
Cancer Hospital between February and October of 2008
performed by a single surgeon (RA) whose practice is
dedicated solely to robotic urologic surgery. The source of
referral was recorded during scheduling for the initial
office visit and by patient-reported questionnaire and kept
in a deidentified, prospective database. Patients were spe-
cifically asked to report whether their presentation for
RALP was due to a newspaper, radio, or magazine adver-
tisement or article, information found on the Internet,
referral by a family member or friend including previous
patients, or referral by another physician (with specifica-
tion of the physician). Preoperative patient characteristics
including demographic data, history of previous abdomi-
nal surgery, PSA, and biopsy pathology were also re-
corded prospectively as was postoperative pathology.
RESULTS
Of 200 consecutive patients, 181 were referred by their
diagnosing urologist (90.5%). Of these, only 11 patients
were diagnosed and referred by urologists at the same
institution as the RALP surgeon. Only 10 patients (5%)
cited any media source as the reason for presentation for
RALP, and only 3 patients (1.5%) were referred by their
primary care physician rather than their urologist. The
remaining 6 patients (3%) indicated that they were re-
ferred by a family member or friend. When comparing the
first 100 patients in the group with the second 100, no
difference was found in the proportion of referrals from
each source (90 vs. 91 by urologist, 5 vs. 5 by media, 2 vs.
1 by primary care physician, and 3 vs. 3 by family/friend).
The mean patient age was 60.5 years (range, 41 to 80) with
mean body mass index (BMI) of 30kg/m
2 (range, 19 to
51). The median preoperative Gleason score was 7 (range,
6 to 9), and the mean PSA was 7.36ng/mL (range, 0.76 to
114.5). The mean gland size was 55.61g (range, 25.5 to
151.7). Of the 200 patients, 148 (74%) had T2 disease on
final pathology with a mean tumor volume of 17.7% (5%
to 60%), and 52 (26%) patients had T3 disease with a mean
of 41.2% (range, 10% to 90%) tumor volume.
Of the patients specifically referred by an urologist, the
mean patient BMI was 36kg/m
2 (range, 21–51). Among
these patients, 36% had a history of previous abdominal or
prostate surgery for benign hyperplasia, and their mean
prostate size was 54.5g (range, 34.4 to 148.1).
At this time, we lack comparison between university and
nonuniversity settings on referral patterns for RALP, be-
cause nonuniversity practices do not typically compile
such databases of their prostatectomy patients.
DISCUSSION
As treatments for prostate cancer have evolved and be-
come more numerous, health-related quality of life out-
comes have become increasingly important in guiding
treatment choices for men with early disease. Although
both surgery and radiation therapy may have substantial
effects on psychosocial and functional wellbeing,9–15
some have suggested that men undergoing prostatectomy
have better mental health, fewer emotional problems,
more vitality and higher social function compared with
men choosing radiation or watchful waiting.15 If indeed
RALP can further improve upon this with less blood loss,
need for transfusion, postoperative pain, and hospital
stay,16–20 these benefits may be a strong compeller to-
wards RALP.
Currently, no other center performing RALP has reported
on referral patterns and the nature of cases being referred.
Palmer et al21 reported on the source of referral for those
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after a robotic program was established (FY2006) by a
since relocated surgeon. During that period, only 55% of
patients had been referred by another physician (of any
specialty), while 90% of the patients in our current study
were referred specifically by urologists.
We believe this finding suggests acceptance of RALP as a
mode of surgical treatment for patients with prostate can-
cer. During the same time period when these procedures
were performed, 1% of all prostatectomies performed at
our institution were performed in open fashion by other
surgeons. In fact, during the short period of time when
RALP was not offered at our institution (after relocation of
the previous RALP surgeon), referrals for prostatectomy to
our institution declined by more than 90%, reflecting again
that urologists were preferentially referring for RALP in
particular and not for open prostatectomy or prostate
cancer treatment in general.
One limitation of this retrospective study is that the reason
for referrals was not recorded along with the source and
does not completely exclude the possibility that marketing
remains a motivating factor. Although we believe that the
resurrection of our RALP program and continued success
reflects a belief in RALP by urologists in our region rather
than marketing to patients or their families, it is possible
that these same urologists are referring patients because
they have demanded RALP after exposure to some mar-
keting campaign. It should be noted that during this pe-
riod our institution did not market robotic surgery in any
way other than mailing announcements regarding the
new robotic surgeon to physicians in the region.
Based on the information available, quantitation or assess-
ment of how advertising influences referral patterns across
regions where advertising is likely more prevalent would
be valuable but is lacking at this point.
Also, although we have anecdotally had few patients who
were self-referred because their diagnosing urologist re-
fused to refer them for RALP, it has been much more
common in our experience that patients were unaware of
RALP until it was discussed with the referring urologist.
Further evidence corroborating our belief is the complex-
ity of patients referred, as not only does this reflect in-
creased confidence in RALP among referring urologists,
but these complex patients could easily have been denied
referral and told that they were not candidates for RALP
due to anatomic concerns or cancer severity.
CONCLUSION
Based on our findings, the referral pattern for RALP at our
institution may reflect a growing acceptance of robotic
surgery among urologists in our region, because the vast
majority of patients presenting for RALP presented due to
urologist referral and not due to marketing or “word-of-
mouth.” Additionally, urologists referred even complex
and higher-risk patients for RALP, potentially reflecting
increased comfort with RALP as a treatment modality for
all patients who are candidates for prostatectomy.
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